AMGN : Summary for Amgen Inc. - Yahoo Finance

U.S. Markets closed

Amgen Inc. (AMGN)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
163.06-1.65 (-1.00%)
At close: 4:00PM EDT

163.05 -0.01 (-0.01%)
After hours: 4:18PM EDT

People also watch
BIIBGILDCELGMRKBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close164.71
Open164.47
Bid162.42 x 300
Ask163.05 x 100
Day's Range162.94 - 165.22
52 Week Range133.64 - 184.21
Volume3,416,371
Avg. Volume4,073,024
Market Cap120.09B
Beta1.76
PE Ratio (TTM)15.92
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield4.60 (2.79%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire12 minutes ago

    FDA Grants Priority Review For Amgen's BLINCYTO® (blinatumomab) Supplemental Biologics License Application

    THOUSAND OAKS, Calif., March 29, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License ...

  • PR Newswire16 minutes ago

    Journal Of Clinical Oncology Publishes Data On BLINCYTO® (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

    THOUSAND OAKS, Calif., March 29, 2017 /PRNewswire/ -- Amgen (AMGN) today announced that the Journal of Clinical Oncology published results from the Phase 2, open-label ALCANTARA study evaluating the efficacy and safety of BLINCYTO® (blinatumomab) in patients with Philadelphia chromosome-positive (Ph+) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) who had failed at least one second-generation or later tyrosine kinase inhibitor (TKI). The study, one of the largest conducted in this patient population (n=45), found that 16 patients (36 percent, 95 percent CI, 22−51 percent) achieved complete remission or complete remission with partial hematologic recovery within the first two cycles of treatment, with 14 of the 16 (31 percent, 96 percent CI, 18–47 percent) patients achieving complete remission with full hematologic recovery.

  • 3 Drugmakers With Boatloads of Cash to Spend
    Motley Fool37 minutes ago

    3 Drugmakers With Boatloads of Cash to Spend

    Johnson & Johnson, Amgen, and Gilead Sciences currently rank as the most cash-rich drugmakers -- but Pfizer could knock one of them out of its spot soon.